Clear All
765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
N/A Ensartinib ENSACOVE 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Yes 2025 In Use
NA Fluoxymesterone Androxy 10 mg Hormonal Therapy Androgen Yes 1983 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Axitinib Axitinib 1 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Dasatinib Sprycel 20 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Cyclosporine NeOral 25mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 1995 In Use
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
J8999 Chemotherapy - non specific Prescription drug, oral, chemotherapeutic NOS NA Chemotherapy Yes In Use
NA Belumosudil Rezurock 200mg Chemotherapy Rho Kinase Inhibitor ROCK1, ROCK2 Yes 2021 In Use
NA Thioguanine Tabloid 40 mg Chemotherapy Antimetabolite Purine Analog Yes 1966 In Use
N/A Avutometinib potassium and defactinib hydrochloride AVMAPKI FAKZYNJA CO-PACK 0.8mg and 200mg Chemotherapy MEK Inhibitor, Tyrosine Kinase Inhibitor MEK1/2, ERK1/2, KRAS Yes 2025 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
NA Pirtobrutinib Jaypirca Multiple Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2023 In Use
NA Raloxifene Hydrochloride Evista 60 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1997 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
NA Bexarotene Targretin 75mg Chemotherapy Immunomodulator Retinoic Acid Derivative Yes 2014 In Use
NA Nintedanib Ofev 150 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Yes 2014 In Use
NA Pomalidomide Pomalyst 2 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Thalidomide Thalomid 200 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Bicalutamide Casodex 50 mg Hormonal Therapy Androgen Receptor Inhibitor non-steriodal Yes 1995 In Use
NA Thalidomide Thalomid 100 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Enasidenib mesylate Idhifa 50 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
NA Abemaciclib Verzenio 100 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.